Cart
sales@molnova.com
Propargyl-PEG3-acid
CAS No. 1347760-82-0
Propargyl-PEG3-acid ( —— )
Catalog No. M23509 CAS No. 1347760-82-0
Propargyl-PEG3-acid is a non-cleavable (3 unit PEG) ADC linker and also a PEG-based PROTAC linker that can be used to synthesis 6-OHDA-PEG3-yne.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 38 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePropargyl-PEG3-acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionPropargyl-PEG3-acid is a non-cleavable (3 unit PEG) ADC linker and also a PEG-based PROTAC linker that can be used to synthesis 6-OHDA-PEG3-yne.
-
DescriptionPropargyl-PEG3-acid is a non-cleavable (3 unit PEG) ADC linker and also a PEG-based PROTAC linker that can be used to synthesis 6-OHDA-PEG3-yne. 6-OHDA-PEG3-yne contains 6-OHDA and Propargyl-PEG3-acid.
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPEGs;Non-cleavable
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1347760-82-0
-
Formula Weight216.2
-
Molecular FormulaC10H16O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(O)CCOCCOCCOCC#C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Farzam A, et al. A functionalized hydroxydopamine quinone links thiol modification to neuronal cell death. Redox Biol. 2020 Jan;28:101377.
molnova catalog
related products
-
dBET57
dBET57 is a potent and selective degrader of BRD4BD1 based on the PROTAC technology. dBET57 mediates recruitment to the CRL4CRBN E3 ubiquitin ligase, with a DC50/5h of 500 nM for BRD4BD1, and is inactive on BRD4BD2.
-
Bromo-PEG2-CH2-Boc
Bromo-PEG2-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
HDAC6 degrader 9c
HDAC6 degrader 9c (dHDAC6 9c) is a bifunctional molecule (dHDAC6) that could selectively degrade HDAC6, by conjugating non-selective HDAC inhibitor to a thalidomide-type E3 ligase ligand.
